drugset / Trial / NCT07235683
Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of the CLEAR-CMV trial is to evaluate the efficacy of letermovir therapy plus standard of care (SOC) antiviral compared to SOC plus placebo in achieving clearance of CMV viremia by week 3 in lung transplant recipients with active CMV infection.
Timeline
- Start
- 2025-12-24
- Primary completion
- 2027-08
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letermovir | Small molecule | 480 mg | Oral |
| Background | Ganciclovir | Small molecule | — | — |
| Background | Valganciclovir | Small molecule | — | — |